Industry News (Clinical Trials)

Trial Results May Provide Direct Delivery of Neurotrophic Factor

Published in Gene Therapy Weekly, December 4th, 1995

CytoTherapeutics, Inc., Providence, Rhode Island, announced that Patrick Aebischer, M.D., Ph.D., a founding scientist of the company, reported preliminary results from a pilot clinical study of its novel amyotrophic lateral sclerosis (ALS) therapeutic product at the 25th Annual Meeting of the Society for Neuroscience in San Diego, California.

The ten-patient study is the first reported human clinical trial for a cell-containing implant to deliver a recombinant protein within the central nervous system (CNS). Aebischer's study demonstrated the successful delivery of targeted levels of ciliary neurotrophic factor (CNTF), a growth factor under investigation to treat ALS. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-12-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry